A Phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-10203 in subjects with advanced solid tumors (The BREAKER-101 Trial)

Disease:

Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer, HER2-positive Advanced Breast Cancer

Study phase:

Phase I

Physician name:

Jordi Rodon Ahnert

Department:

Investigational Cancer Therapeutics

For general questions about clinical trials:

1-877-632-6789